Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.

Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 12 01; 37(34):3243-3255.

View in: PubMed

subject areas

Age Factors
Algorithms
Antineoplastic Combined Chemotherapy Protocols
Child
Child, Preschool
Clinical Decision-Making
Decision Support Techniques
Drug Administration Schedule
Female
Humans
Infant
Infant, Newborn
Male
Neoadjuvant Therapy
Neoplasm Staging
Neuroblastoma
Prospective Studies
Risk Assessment
Risk Factors
Time Factors
United States

authors with profiles

Susan L. Cohn